Table 1.
MSC clinical trials for immune-related diseases
| MSC source | Total % | Total No. | No. of clinical trial phases | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ? | 0 | 1 | 1 & 2 | 2 | 2 & 3 | 3 | 4 | |||
| Unspecified | 21.0 | 49 | 1 | 0 | 9 | 21 | 14 | 3 | 1 | 0 |
| Bone marrow | 41.2 | 96 | 3 | 1 | 21a | 38 | 25 | 3 | 5 | 0 |
| Adipose tissue | 16.3 | 38 | 0 | 1 | 10 | 17 | 7 | 1 | 2 | 0 |
| Umbilical cord | 14.2 | 33 | 0 | 0 | 6ab | 22 | 4c | 0 | 0 | 1 |
| Umbilical cord blood | 5.6 | 13 | 0 | 0 | 3 | 4 | 3 | 1 | 2 | 0 |
| Placenta | 1.3 | 3 | 0 | 0 | 2b | 0 | 1c | 0 | 0 | 0 |
| Menstrual Blood | 0.4 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Total No. of clinical trial phases | 230 | 4 | 2 | 49d | 103 | 53e | 8 | 10 | 1 | |
| Total % of clinical trial phases | 1.7 | 0.9 | 21.3 | 44.8 | 23.0 | 3.5 | 4.3 | 0.4 | ||
abcMSCs are applied to the same clinical trials
deNumber of total clinical trial phase 1 and phase 2 withdraw duplicated MSC source number in the same clinical trials